• 1
    Acharya M, Borland G, Edkins AL, Matheson J, MacLellan LJ, Ozanne BW, Cushley W. CD23: molecular multi-tasking. Clin Exp Immunol 2010; 162:1223.
  • 2
    Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, Graber P, Aubry JP, Jeannin P, Plater-Zyberk C. Structure and functions of CD23. Int Rev Immunol 1997; 16:11328.
  • 3
    Conrad DH, Ford JW, Sturgill JL, Gibb DR. CD23: an overlooked regulator of allergic disease. Curr Allergy Asthma Rep 2007; 7:3317.
  • 4
    Yukawa K, Kikutani H, Owaki H et al. A B cell-specific differentiation antigen, CD23, is a receptor for IgE (FcεR) on lymphocytes. J Immunol 1987; 138:257680.
  • 5
    Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992; 358:5057.
  • 6
    Aubry JP, Pochon S, Gauchat JF, Nueda-Marin A, Holers VM, Graber P, Siegfried C, Bonnefoy JY. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J Immunol 1994; 152:580613.
  • 7
    Bjorck P, Elenstrom-Magnusson C, Rosen A, Severinson E, Paulie S. CD23 and CD21 function as adhesion molecules in homotypic aggregation of human B lymphocytes. Eur J Immunol 1993; 23:17715.
  • 8
    Laitinen T, Ollikainen V, Lazaro C et al. Association study of the chromosomal region containing the FCER2 gene suggests it has a regulatory role in atopic disorders. Am J Respir Crit Care Med 2000; 161(3 Pt 1):7006.
  • 9
    Yu P, Kosco-Vilbois M, Richards M, Kohler G, Lamers MC. Negative feedback regulation of IgE synthesis by murine CD23. Nature 1994; 369:7536.
  • 10
    Payet M, Conrad DH. IgE regulation in CD23 knockout and transgenic mice. Allergy 1999; 54:11259.
  • 11
    Lewis G, Rapsomaniki E, Bouriez T et al. Hyper IgE in New Zealand black mice due to a dominant-negative CD23 mutation. Immunogenetics 2004; 56:56471.
  • 12
    Weskamp G, Ford JW, Sturgill J et al. ADAM10 is a principal ‘sheddase’ of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 2006; 7:12938.
  • 13
    Gordon J, Flores-Romo L, Cairns JA, Millsum MJ, Lane PJ, Johnson GD, MacLennan IC. CD23: a multi-functional receptor/lymphokine? Immunol Today 1989; 10:1537.
  • 14
    Liu YJ, Cairns JA, Holder MJ, Abbot SD, Jansen KU, Bonnefoy JY, Gordon J, MacLennan IC. Recombinant 25-kDa CD23 and interleukin 1α promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991; 21:110714.
  • 15
    Borland G, Edkins AL, Acharya M et al. αVβ5 integrin sustains growth of human pre-B cells through an RGD-independent interaction with a basic domain of the CD23 protein. J Biol Chem 2007; 282:2731526.
  • 16
    White LJ, Ozanne BW, Graber P, Aubry JP, Bonnefoy JY, Cushley W. Inhibition of apoptosis in a human pre-B-cell line by CD23 is mediated via a novel receptor. Blood 1997; 90:23443.
  • 17
    Lecoanet-Henchoz S, Gauchat JF, Aubry JP et al. CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity 1995; 3:11925.
  • 18
    Hermann P, Armant M, Brown E et al. The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23. J Cell Biol 1999; 144:76775.
  • 19
    Rezzonico R, Chicheportiche R, Imbert V, Dayer JM. Engagement of CD11b and CD11c β2 integrin by antibodies or soluble CD23 induces IL-1β production on primary human monocytes through mitogen-activated protein kinase-dependent pathways. Blood 2000; 95:386877.
  • 20
    Rezzonico R, Imbert V, Chicheportiche R, Dayer JM. Ligation of CD11b and CD11c β2 integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1α (MIP-1α) and MIP-1β production in primary human monocytes through a pathway dependent on nuclear factor-κB. Blood 2001; 97:293240.
  • 21
    Takei M, Azuhata T, Yoshimatu T, Shigihara S, Hashimoto S, Horie T, Horikoshi A, Sawada S. Increased soluble CD23 molecules in serum/saliva and correlation with the stage of sialoectasis in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 1995; 13:7115.
  • 22
    Bansal AS, MacGregor AJ, Pumphrey RS, Silman AJ, Ollier WE, Wilson PB. Increased levels of sCD23 in rheumatoid arthritis are related to disease status. Clin Exp Rheumatol 1994; 12:2815.
  • 23
    Huissoon AP, Emery P, Bacon PA, Gordon J, Salmon M. Increased expression of CD23 in rheumatoid synovitis. Scand J Rheumatol 2000; 29:1549.
  • 24
    Massa M, Pignatti P, Oliveri M, De Amici M, De Benedetti F, Martini A. Serum soluble CD23 levels and CD23 expression on peripheral blood mononuclear cells in juvenile chronic arthritis. Clin Exp Rheumatol 1998; 16:6116.
  • 25
    Plater-Zyberk C, Bonnefoy JY. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo. Nat Med 1995; 1:7815.
  • 26
    Flores-Romo L, Shields J, Humbert Y et al. Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. Science 1993; 261:103841.
  • 27
    Hibbert RG, Teriete P, Grundy GJ et al. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med 2005; 202:75160.
  • 28
    Wurzburg BA, Tarchevskaya SS, Jardetzky TS. Structural changes in the lectin domain of CD23, the low-affinity IgE receptor, upon calcium binding. Structure 2006; 14:104958.
  • 29
    Schulz O, Sutton BJ, Beavil RL, Shi J, Sewell HF, Gould HJ, Laing P, Shakib F. Cleavage of the low-affinity receptor for human IgE (CD23) by a mite cysteine protease: nature of the cleaved fragment in relation to the structure and function of CD23. Eur J Immunol 1997; 27:5848.
  • 30
    Kijimoto-Ochiai S, Noguchi A. Two peptides from CD23, including the inverse RGD sequence and its related peptide, interact with the MHC class II molecule. Biochem Biophys Res Commun 2000; 267:68691.
  • 31
    Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol 2005; 21:381410.
  • 32
    Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12:697715.
  • 33
    Xiong JP, Stehle T, Diefenbach B et al. Crystal structure of the extracellular segment of integrin αVβ3. Science 2001; 294:33945.
  • 34
    Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout MA. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296:1515.
  • 35
    Lecoanet-Henchoz S, Plater-Zyberk C, Graber P, Gretener D, Aubry JP, Conrad DH, Bonnefoy JY. Mouse CD23 regulates monocyte activation through an interaction with the adhesion molecule CD11b/CD18. Eur J Immunol 1997; 27:22904.
  • 36
    Vogel BE, Lee SJ, Hildebrand A, Craig W, Pierschbacher MD, Wong-Staal F, Ruoslahti E. A novel integrin specificity exemplified by binding of the αVβ5 integrin to the basic domain of the HIV Tat protein and vitronectin. J Cell Biol 1993; 121:4618.
  • 37
    Ivaska J, Kapyla J, Pentikainen O, Hoffren AM, Hermonen J, Huttunen P, Johnson MS, Heino J. A peptide inhibiting the collagen binding function of integrin α2I domain. J Biol Chem 1999; 274:351321.
  • 38
    Schober JM, Lau LF, Ugarova TP, Lam SC. Identification of a novel integrin αMβ2 binding site in CCN1 (CYR61), a matricellular protein expressed in healing wounds and atherosclerotic lesions. J Biol Chem 2003; 278:2580815.
  • 39
    Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 1987; 262:1770311.
  • 40
    Armant M, Rubio M, Delespesse G, Sarfati M. Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells. J Immunol 1995; 155:486875.
  • 41
    Bansal A, Roberts T, Hay EM, Kay R, Pumphrey RS, Wilson PB. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren’s syndrome and systemic lupus erythematosus. Clin Exp Immunol 1992; 89:4525.
  • 42
    Yoshikawa T, Nanba T, Kato H, Hori K, Inamoto T, Kumagai S, Yodoi J. Soluble FcεRII/CD23 in patients with autoimmune diseases and Epstein–Barr virus-related disorders: analysis by ELISA for soluble FcεRII/CD23. Immunomethods 1994; 4:6571.
  • 43
    Asokan R, Hua J, Young KA et al. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-α: a potential role in systemic lupus erythematosus. J Immunol 2006; 177:38394.
  • 44
    Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 115:48995.
  • 45
    Sarfati M, Chevret S, Chastang C et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88:425964.
  • 46
    Rambert J, Mamani-Matsuda M, Moynet D et al. Molecular blocking of CD23 supports its role in the pathogenesis of arthritis. PLoS One 2009; 4:e4834.
  • 47
    Wilder RL. Integrin αVβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002; 61(Suppl. 2):ii969.
  • 48
    Coleman KR, Braden GA, Willingham MC, Sane DC. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (αVβ3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res 1999; 84:126876.
  • 49
    Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD. Stepwise in vitro affinity maturation of Vitaxin, an αVβ3-specific humanized mAb. Proc Natl Acad Sci USA 1998; 95:603742.
  • 50
    Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxin – an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001; 92:13478.
  • 51
    Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αVβ3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001; 16:12532.
  • 52
    Hersey P, Sosman J, O’Day S et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α Vβ3, + or − dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010; 116:152634.